<DOC>
	<DOCNO>NCT03083353</DOCNO>
	<brief_summary>The propose study represent crucial important stage translate basic research strategy treat nicotine dependence . The investigation address important public health issue test intervention - informed basic research - may lead effective efficient treatment smoker . The expected finding provide initial effect size data addition isradipine integrate psychosocial/behavioral pharmacological smoking cessation intervention smoker , thus provide necessary data large-scale follow-up trial .</brief_summary>
	<brief_title>Enhancing Cue Exposure Treatment Smoking Reduction With Isradipine</brief_title>
	<detailed_description>The propose proof-of-concept study utilize prospective , experimental research design . The investigator recruit adult daily smoker randomly assign either : ( 1 ) Cue Exposure Treatment Isradipine ( CET+ISR ) ( 2 ) CET placebo ( CET+PBO ) . Two 90-minute CET session conduct expose participant interoceptive situational cue tobacco use craving . In first session , participant receive dose ISR PBO begin CET session wait 75 minute . CET three component : exposure slide depict smoke cue ( visual exposure ) , exposure emotion imagine situation reliably trigger urge smoke ( emotional/imaginal ) , exposure participant 's cigarette ( vivo ) . The second session conduct 24 h first medication-free state . Clinicians record crave throughout CET session . Participants return one week second CET session complete several questionnaire relate smoke mood , provide carbon monoxide sample verify abstinence , report crave smoke related cue .</detailed_description>
	<mesh_term>Tobacco Use Disorder</mesh_term>
	<mesh_term>Isradipine</mesh_term>
	<criteria>Male female patient age 1865 capable provide informed consent Willing able provide inform consent , attend study visit comply protocol Daily smoker least one year Currently smoke average least 10 cigarette per day Report motivation quit smoke next month least 7 10point scale Current diagnosis psychotic , eat , developmental bipolar disorder Significant suicide risk determine structure interview Exclusion criterion related isradipine administration : Potential participant exclude report history follow : 1. know allergy sensitivity isradipine , 2. hypertension , 3. congestive heart failure , 4. type liver disease , 5. current pregnancy , 6. woman childbearing potential use medically accept form contraception ( e.g. , IUD , oral contraceptive , barrier device , condom foam , implant progesterone rod stabilize least 3 month ) . Potential participant also exclude currently take : 1 . Rifampin , 2 . Tagamet . Rifampin show decrease availability calcium channel blocker concurrent administration Tagamet isradipine show increase hypotensive effect inhibit hepatic metabolism isradipine . Psychoactive substance use assess urinalysis A history significant medical condition and/or deem currently unhealthy Dr. Young Limited mental competency inability give inform , voluntary , write consent participate Current use pharmacotherapy psychotherapy smoke cessation provide researcher quit attempt Concurrent psychotherapy initiate within three month screen , ongoing psychotherapy duration direct specifically toward treatment anxiety mood disorder general supportive therapy initiate least 3 month prior study Use tobacco product , include ecigarettes Insufficient command English language</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>